

The Challenges Presented by Hypertrophic Cardiomyopathy in Clinical Practice: How Does Your Approach Compare with the Experts?

Resource	Address
Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i> . 2020;142:e558-e631.	https://pubmed.ncbi.nlm.nih.gov/33215931/
Authors/Task Force members, Elliott PM, Anastasakis A, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). <i>Eur Heart J</i> . 2014;35:2733-2779.	https://pubmed.ncbi.nlm.nih.gov/25173338/
Maron MS, Hellawell JL, Lucove JC, Farzaneh-Far R, Olivotto I. Occurrence of clinically diagnosed hypertrophic cardiomyopathy in the United States. <i>Am J Cardiol</i> . 2016;117:1651-1654.	https://pubmed.ncbi.nlm.nih.gov/27006153/
Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. <i>J Am Coll Cardiol</i> . 2015;65:1249-1254.	https://pubmed.ncbi.nlm.nih.gov/25814232/
Maron BJ. Clinical course and management of hypertrophic cardiomyopathy. <i>N Engl J Med</i> . 2018;379:655-668.	https://pubmed.ncbi.nlm.nih.gov/30110588/
Geske JB, Bos JM, Gersh BJ, Ommen SR, Eidem BW, Ackerman MJ. Deformation patterns in genotyped patients with hypertrophic cardiomyopathy. <i>Eur Heart J Cardiovasc Imaging</i> . 2014;15:456-465.	https://pubmed.ncbi.nlm.nih.gov/24217980/
Maron BJ, Desai MY, Nishimura RA, et al. Diagnosis and evaluation of hypertrophic cardiomyopathy: JACC State-of-the-Art Review. <i>J Am Coll Cardiol</i> . 2022;79:372-389.	https://pubmed.ncbi.nlm.nih.gov/35086660/
Finocchiaro G, Sheikh N, Biagini E, et al. The electrocardiogram in the diagnosis and management of patients with hypertrophic cardiomyopathy. <i>Heart Rhythm</i> . 2020;17:142-151.	https://pubmed.ncbi.nlm.nih.gov/31349064/
Rowin EJ, Maron BJ, Romashko M, et al. Impact of effective management strategies on patients with the most extreme phenotypic expression of hypertrophic cardiomyopathy. <i>Am J Cardiol</i> . 2019;124:113-121.	https://pubmed.ncbi.nlm.nih.gov/31027655/
Chan RH, Maron BJ, Olivotto I, et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. <i>Circulation</i> . 2014;130:484-495.	https://pubmed.ncbi.nlm.nih.gov/25092278/

Neubauer S, Kolm P, Ho CY, et al. Distinct subgroups in hypertrophic cardiomyopathy in the NHLBI HCM Registry. <i>J Am Coll Cardiol</i> . 2019;74:2333-2345.	https://pubmed.ncbi.nlm.nih.gov/31699273/
Rowin EJ, Burrows A, Madias C, et al. Long-term outcome in high-risk patients with hypertrophic cardiomyopathy after primary prevention defibrillator implants. <i>Circ Arrhythm Electrophysiol</i> . 2020;13:e008123.	https://pubmed.ncbi.nlm.nih.gov/32897759/
Maron BJ, Spirito P, Shen WK, et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. <i>JAMA</i> . 2007;298:405-412.	https://pubmed.ncbi.nlm.nih.gov/17652294/
Rowin EJ, Maron BJ, Haas TS, et al. Hypertrophic cardiomyopathy with left ventricular apical aneurysm: Implications for risk stratification and management. <i>J Am Coll Cardiol</i> . 2017;69:761-773.	https://pubmed.ncbi.nlm.nih.gov/28209216/
Maron BJ, Rowin EJ, Maron MS, Braunwald E. Nonobstructive hypertrophic cardiomyopathy out of the shadows: Known from the beginning but largely ignored ... until now. <i>Am J Med</i> . 2017;130:119-123.	https://pubmed.ncbi.nlm.nih.gov/27746287/
Maron MS, Rowin EJ, Olivotto I, et al. Contemporary natural history and management of nonobstructive hypertrophic cardiomyopathy. <i>J Am Coll Cardiol</i> . 2016;67:1399-1409.	https://pubmed.ncbi.nlm.nih.gov/27012399/
Sorajja P, Valeti U, Nishimura RA, et al. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. <i>Circulation</i> . 2008;118:131-139.	https://pubmed.ncbi.nlm.nih.gov/18591440/
Liebrechts M, Vriesendorp PA, Mahmoodi BK, Schinkel AF, Michels M, ten Berg J. A systematic review and meta-analysis of long-term outcomes after septal reduction therapy in patients with hypertrophic cardiomyopathy. <i>JACC Heart Fail</i> . 2015;3:896-905.	https://pubmed.ncbi.nlm.nih.gov/26454847/
Kim LK, Swaminathan RV, Looser P, et al. Hospital volume outcomes after septal myectomy and alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy: US nationwide inpatient database, 2003-2011. <i>JAMA Cardiol</i> . 2016;1:324-332.	https://pubmed.ncbi.nlm.nih.gov/27438114/
Olivotto I, Oreziak A, Barriaes-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): A randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet</i> . 2020;396:759-769.	https://pubmed.ncbi.nlm.nih.gov/32871100/
Maron MS, Ommen SR. Exploring new and old therapies for obstructive hypertrophic cardiomyopathy: Mavacamten in perspective. <i>Circulation</i> . 2021;143:1181-1183.	https://pubmed.ncbi.nlm.nih.gov/33750209/